A Phase II Enrichment Study of Panitumumab as a Single Agent or in Combination With Trametinib in Cetuximab-Refractory Stage IV Colorectal Cancer Patients
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 30 Oct 2017
At a glance
- Drugs Panitumumab (Primary) ; Trametinib (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- 23 Oct 2017 Planned End Date changed from 1 Sep 2021 to 1 Apr 2022.
- 23 Oct 2017 Planned primary completion date changed from 1 Sep 2021 to 1 Apr 2022.
- 23 Oct 2017 Planned initiation date changed from 1 Sep 2017 to 1 Apr 2018.